Thursday, February 7, 2013

Sandoz launches first generic version of Cleocin Phosphate® in Dextrose 5%


Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of clindamycin in 5% dextrose in minibag form, the first generic version of Cleocin Phosphate® in Dextrose 5%.
Clindamycin in 5% dextrose is an antibiotic indicated for the treatment of serious bacterial infections.

According to IMS Health, US sales for the branded version of clindamycin in 5% dextrose were USD 52.2 million for the 12 months ending in December 2012. Sandoz is marketing clindamycin in 5% dextrose in the same strengths as those of the originator brand


Enter your email address:


Delivered by FeedBurner